Chippewa Valley Angels Investment Network
P.O. Box 3232, Eau Claire, WI, United States
Overview
The Chippewa Valley Angel Investors Network, LLC was organized in 2003 to meet a need identified in the region by providing private equity financing potential for early stage and start-up entrepreneurial ventures in the greater Chippewa Valley. Supported by Momentum West, the network is owned and operated by its member angel investors. It meets monthly to view presentations from businesses that have been pre-screened and invited to present. By the end of 2009 the CVAIN membership has invested over $3 million in seven early stage companies in the Chippewa Valley and surrounding region, including the Twin Cities and Madison.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Investment portfolio
- Biosystem Development
Participated · Equity · Nov 2009
BioSystem Development creates, manufactures and markets the AssayMAP microchromatography technology, a platform based on disposable micro‑chromatography cartridges and automation. The AssayMAP platform enables high-throughput solutions for bioprocess development, biomarkers and general life‑science research that reduce development time and increase efficiency. The company markets patented AssayMAP® technology and recently launched the fully automated AssayMAP Bravo® system, co-developed with Agilent Technologies. BioSystem Development intends to use new funding to scale up manufacturing capabilities, accelerate time to market for new products and support pipeline expansion. The company said demand from strategic partners has increased following the Bravo launch. BioSystem Development was established in 2002 and is based in Madison, Wis. BioSystem Development, founded in 2002 and based in Madison, Wis., designs, manufactures and markets tools and products to meet the needs of pharmaceutical development. Its core product is the AssayMAP platform, which is based on disposable micro‑chromatography cartridges and automation. The AssayMAP platform enables high‑throughput solutions for bioprocess development, biomarkers and general life‑science research. In November 2010 the company completed a $978,000 funding round. The capital will enable the company to expand its manufacturing infrastructure and to launch new AssayMAP products into the biopharmaceutical development market. Founder and CEO Scott Fulton said the funding provides the means to respond to growing market interest and launch several disruptive AssayMAP products. BioSystem Development, LLC develops and manufactures the AssayMAP™ Bioanalysis System, an open platform intended to improve analytical workflows for biopharmaceutical process development. The company completed an over $1.4M investment round composed of capital equipment and funding. Two strategic manufacturing partners, All Metal Stamping and Orbital Biosciences, contributed $350,000 in tooling and manufacturing infrastructure. The remaining just over $1.0M came from current investors and new contributors, including groups from Marshfield Investment Partners, Silicon Pastures and the Chippewa Valley Angel Investors Network. Management said the funding will support formalizing key strategic technology and commercial partnerships. The company also plans to use proceeds to launch several new AssayMAP products.
Team
No current team members are available.